Pharmaceuticals

The man, diagnosed with an autoimmune disorder, said he was reassured the drugmaker’s copay card would cover his share, but after two months, the card was empty.

Michael Emanuel Rajner says lawmakers are willing to shore up a purported $120 million deficit in the medication program and the health department "needs to stand down."

The measure would let people sue vaccine manufacturers if the drugs advertised in the state harm them.

The federal government’s Vaccine Injury Compensation Program was supposed to help patients with their medical bills while protecting vaccine supply. But allies of the HHS secretary routinely transfer cases to launch lawsuits against drugmakers.

Insurers will take drug costs, frequency of use and other factors into account as they set premium amounts for the 2026 plan year.

A new drug is helping families who've spent years locking up or hiding food as their children with Prader-Willi syndrome deal with unrelenting hunger. But additional progress is under threat.

The AP-NORC survey shows about half of U.S. adults believe it is a good thing for adults to use Ozempic, Wegovy and similar GLP-1 drugs if they are struggling with weight. That support doesn't go for teens.

The most popular nasal decongestant on U.S. pharmacy shelves may not be there much longer. The FDA recently announced plans to phase out phenylephrine.

The guidelines took years to finalize, but while regulators were drafting them, a new trend emerged: online pharmaceutical influencers with little government oversight.

The pharmaceutical industry has invented a new art form: finding ways to make their wares seem like joyous must-have treatments, while often minimizing lackluster efficacy and risks.

The FDA considers plants that have gone more than five years without an inspection to be a significant risk. Officials say the work has been hampered by difficulties recruiting and retaining inspectors.

About 350 million people suffer from rare diseases, most of which are genetic. But the individual disorders affect relatively few people, so there’s little commercial incentive to bring these treatments to market.